138 related articles for article (PubMed ID: 17099560)
1. [Methadone: from pharmacokinetic profile to clinical pharmacology].
Vazquez V; Gury C; Laqueille X
Encephale; 2006; 32(4 Pt 1):478-86. PubMed ID: 17099560
[TBL] [Abstract][Full Text] [Related]
2. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.
Eap CB; Buclin T; Baumann P
Clin Pharmacokinet; 2002; 41(14):1153-93. PubMed ID: 12405865
[TBL] [Abstract][Full Text] [Related]
3. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility.
Wolff K; Rostami-Hodjegan A; Hay AW; Raistrick D; Tucker G
Addiction; 2000 Dec; 95(12):1771-83. PubMed ID: 11177493
[TBL] [Abstract][Full Text] [Related]
4. [Methadone treatment and its dangers].
Reingardiene D; Jodziūniene L; Lazauskas R
Medicina (Kaunas); 2009; 45(5):419-25. PubMed ID: 19535889
[TBL] [Abstract][Full Text] [Related]
5. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
6. Appropriateness of methadone maintenance treatment for opiate addiction: evaluation by an expert panel.
Vader JP; Hämmig R; Besson J; Eastus C; Eggenberger C; Burnand B
Soz Praventivmed; 2003; 48 Suppl 1():S1-14. PubMed ID: 12891872
[TBL] [Abstract][Full Text] [Related]
7. [Drug interactions of methadone with CNS-active agents].
Moreno Brea MR; Rojas Corrales O; Gibert-Rahola J; Micó JA
Actas Esp Psiquiatr; 1999; 27(2):103-10. PubMed ID: 10380152
[TBL] [Abstract][Full Text] [Related]
8. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
Foster RH; Goa KL
CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
[TBL] [Abstract][Full Text] [Related]
9. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir.
McCance-Katz EF; Rainey PM; Smith P; Morse G; Friedland G; Gourevitch M; Jatlow P
Am J Addict; 2004; 13(2):163-80. PubMed ID: 15204667
[TBL] [Abstract][Full Text] [Related]
10. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine.
Iribarne C; Picart D; Dréano Y; Berthou F
Fundam Clin Pharmacol; 1998; 12(2):194-9. PubMed ID: 9565774
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment.
Shiran MR; Lennard MS; Iqbal MZ; Lagundoye O; Seivewright N; Tucker GT; Rostami-Hodjegan A
J Clin Psychopharmacol; 2012 Oct; 32(5):666-71. PubMed ID: 22926601
[TBL] [Abstract][Full Text] [Related]
12. [Abuse of alcohol and benzodiazepine during substitution therapy in heroin addicts: a review of the literature].
Laqueille X; Launay C; Dervaux A; Kanit M
Encephale; 2009 Jun; 35(3):220-5. PubMed ID: 19540407
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring in methadone maintenance: choosing a matrix.
Moolchan ET; Umbricht A; Epstein D
J Addict Dis; 2001; 20(2):55-73. PubMed ID: 11318398
[TBL] [Abstract][Full Text] [Related]
14. Craving and drug reward: a comparison of methadone and clonidine in detoxifying opiate addicts.
Dawe S; Gray JA
Drug Alcohol Depend; 1995 Oct; 39(3):207-12. PubMed ID: 8556969
[TBL] [Abstract][Full Text] [Related]
15. Effects of a single 50% extra dose of methadone on heroin craving and mood in lower- versus higher-dose methadone patients.
Strasser J; Wiesbeck GA; Meier N; Stohler R; Dürsteler-Macfarland KM
J Clin Psychopharmacol; 2010 Aug; 30(4):450-4. PubMed ID: 20571436
[TBL] [Abstract][Full Text] [Related]
16. Additional methadone increases craving for heroin: a double-blind, placebo-controlled study of chronic opiate users receiving methadone substitution treatment.
Curran HV; Bolton J; Wanigaratne S; Smyth C
Addiction; 1999 May; 94(5):665-74. PubMed ID: 10563031
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of methadone in healthy subjects and opiate users.
Wolff K; Rostami-Hodjegan A; Shires S; Hay AW; Feely M; Calvert R; Raistrick D; Tucker GT
Br J Clin Pharmacol; 1997 Oct; 44(4):325-34. PubMed ID: 9354306
[TBL] [Abstract][Full Text] [Related]
18. Association of CYP2D6 ultrarapid metabolizer genotype with deficient patient satisfaction regarding methadone maintenance treatment.
Pérez de los Cobos J; Siñol N; Trujols J; del Río E; Bañuls E; Luquero E; Menoyo A; Queraltó JM; Baiget M; Alvarez E
Drug Alcohol Depend; 2007 Jul; 89(2-3):190-4. PubMed ID: 17234366
[TBL] [Abstract][Full Text] [Related]
19. [Reimbursement of opiate substitution drugs to militaries in 2007].
d'Argouges F; Desjeux G; Marsan P; Thevenin-Garron V
Encephale; 2012 Sep; 38(4):304-9. PubMed ID: 22980471
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
